What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 5 months ago
10% of PsA is PsA Sine Psoriasis - how to differentiate from seroneg RA? PsA sine PsO pts have peripheral arthritis, no skin dz, but may have axial sxs, +Family Hx or nail psoriasis, dactylitis, enthesitis, DIP involvement. https://t.co/TijVEc9Uw7 https://t.co/W6C1CTYbA9
Dr. John Cush RheumNow
3 years 5 months ago
About 1 in 7 systemic JIA are "refractory" to standard Rx. Could the definition be active systemic or arthritic disease, despite IL-1 or IL-6 inhibitors? It could also include pts developing MAS, ILD or amyloidosis. Still, there are many Rx options. https://t.co/VBeHhHEtqW https://t.co/67c5Emo337
Dr. Rachel Tate uptoTate
3 years 5 months ago
Outside of meetings/journals and Twitter where do you find info/education you need? @rheum_cat @anisha_dua @KDAO2011 @BolekBerqui @doctorRBC @DrBhana @melodychungmd @got_rheum @philipcrobinson @EBRheum @DamanLangguth @CCalabreseDO
Dr. John Cush RheumNow
3 years 5 months ago
Watch: Comanagement of Psoriasis and Psoriatic Arthritis
https://t.co/N06bioibtm https://t.co/ghb81zF7tV
Dr. John Cush RheumNow
3 years 5 months ago
2021 GRAPPA Recommendations - Looking Back, Looking Forward
https://t.co/JzRCnh43QJ https://t.co/164AdDZCWz
The BMJ has published the results of a metanalysis showing strong conclusive evidence that viscosupplementation in knee osteoarthritis (kOA) has minimal effects on kOA pain, and also reveals strong evidence of an increased risk of serious adverse events.
Dr. John Cush RheumNow
3 years 5 months ago
MTX + Pegloticase Combo FDA Approved
Horizon has announced that the FDA has approved the expanded labeling of pegloticase (Krystexxa) injection to be co-administered with methotrexate (MTX), to improve response rates in patients with uncontrolled gout.
https://t.co/z5b8xxcrOD https://t.co/s6PynSgqNk
Adding a corticosteroid shot to exercise therapy significantly improved symptoms of chronic Achilles tendinopathy, a 100-person randomized trial found.
Dr. John Cush RheumNow
3 years 5 months ago
#EULAR2022 POS0285
130K UK patients had incident gout bw 2004-2020
⭐️Only 29% started on ULT w/in 12 mos
⭐️Target urate level only 14% in 2004, only to 17% in 2020
Updated EULAR guidelines in 2016: No statistical difference in ULT Rx or target attainment
cc: @ericdeinmd https://t.co/nWUM90wRQr
Dr. John Cush RheumNow
3 years 5 months ago
N.Zealand adult registry of ~1million without CV disease, amongst whom 32K had gout. Having gout increased risk of CV events in women (adj HR 1.34;1.23-1.45) and men (1.18). CV risk in men was increased if not on ULT & not at target (~15%) https://t.co/AgHF45kY2c https://t.co/KzRvtMjS9p
Still’s disease and autoinflammatory disorders are rare conditions unified by recurrent fevers and inflammation of skin, joints, and other organs. While labs often support the diagnosis, these conditions are best diagnosed by genetic testing, or by specific criteria (in the absence of a genetic test). The following is a table that lists common misconceptions (myths) and their clarifying explanations.
Dr. John Cush RheumNow
3 years 5 months ago
Study of 420 active #AS patients not responding to bDMARDs (TNFi, IL-17i) randomised to upadacitinib 15 mg/d or placebo. By wk14, UPA was superior by ASAS40 (45 vs 18%; p<0.0001)& other secondary endpoints (p<0.0001). https://t.co/nfOLlxgP5d https://t.co/fROMep8tbT
Dr. John Cush RheumNow
3 years 5 months ago
JAMA full read on wt loss and type 2 diabetes.
- Diet, physical activity, & behavioral therapy
- high frequency counseling (≥16 sessions/6 mos)
- Wt medications effective as adjuncts to diet etc
- Rec surgery if BMI >40, unable to lose # or comorbidity
https://t.co/lgbNVPr8tz https://t.co/bzmdOvnxC7
Poster Hall